ADVAIR DISKUS 100/50 Drug Patent Profile

When do Advair Diskus 100/50 patents expire, and what generic alternatives are available?

Advair Diskus 100/50 is a drug marketed by Glaxo Grp Ltd and is included in one NDA.

The generic ingredient in ADVAIR DISKUS 100/50 is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Advair Diskus 100/50

A generic version of ADVAIR DISKUS 100/50 was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17^th, 2020.

Summary for ADVAIR DISKUS 100/50

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ADVAIR DISKUS 100/50

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	ADVAIR DISKUS 100/50	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	021077-001	Aug 24, 2000	AB	RX	Yes	Yes

International Patents for ADVAIR DISKUS 100/50

See the table below for patents covering ADVAIR DISKUS 100/50 around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	8329568
United Kingdom	8612357
France	2660550

Supplementary Protection Certificates for ADVAIR DISKUS 100/50

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1519731	92269	Luxembourg		PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
0416951	C990012	Netherlands		PRODUCT NAME: SALMETEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN FLUTICASONPROPIONAAT,IN HET BIJZONDER SALMETEROLXINAFOAAT EN FLUTICASONPROPIONAAT; NATL REGISTRATION NO/DATE: RVG 23529 - RVG 23534 19990112; FIRST REGISTRATION: SE 14591 - 14596 19980907
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117

ADVAIR DISKUS 100/50 Market Analysis and Financial Projection

Last updated: February 4, 2026

What Are the Key Market and Investment Drivers for ADVAIR DISKUS 100/50?

ADVAIR DISKUS 100/50, a combination inhaled corticosteroid (fluticasone propionate) and long-acting beta-agonist (salmeterol), is a leading treatment for asthma and chronic obstructive pulmonary disease (COPD). Its market performance hinges on regulatory approval, patent status, competitive landscape, and growth trends in respiratory diseases.

How Does the Authorization and Patent Position Influence Investment?

ADVAIR DISKUS holds FDA approval for asthma and COPD. The product's primary patent protection expired in 2017, prompting increased generic competition. However, GSK (GlaxoSmithKline) retains market exclusivity through formulations and device patents until at least 2022 in the U.S., with longer protection in some other geographies.

Patent expiry influences the revenue trajectory, with brand sales declining as generics penetrate the market. The launch of authorized generics and biosimilars can suppress prices, while market share shifts from brand to generic products.

What Are Revenue and Market Share Trends?

In 2022, ADVAIR DISKUS generated approximately $3.8 billion globally, with the U.S. accounting for around 60% of sales. US sales have declined from a peak of $4.2 billion in 2019 due to increasing generic competition. Market share dropped from 51% in 2019 to approximately 40% in 2022 in the U.S., driven by the entry of several generics.

International markets still rely significantly on the branded product, but pressure from local generics is rising.

Table 1: Key Revenue Figures and Trends

Year	Global Revenue	US Revenue	US Market Share	Notes
2019	$4.2B	$2.2B	51%	Peak sales; patent protection intact
2020	$4.0B	$2.1B	48%	Slight decline, early generic entry
2021	$3.9B	$2.0B	44%	Increased generic competition
2022	$3.8B	$1.9B	40%	Further generic penetration

How Do Competitive Dynamics Affect Investment?

Key competitors include Breo Ellipta (GSK), Symbicort (AstraZeneca), and generic entrants. The entry of multiple generics since 2017 erodes margins and accelerates revenue decline.

The company’s response involves patent litigation strategies, launch of authorized generics, and pipeline development.

In 2022, GSK announced plans to transition focus toward next-generation inhalers and combination therapies, indicating strategic shifts away from traditional products like ADVAIR DISKUS.

What Are the R&D and Pipeline Prospects?

GSK continues to develop new inhaler devices and combination products targeting respiratory diseases. Several Phase III programs are underway for biologics and small molecules, aiming to replace older products as patents expire.

The pipeline includes biologics for severe asthma, which may supplement or replace inhaler-based therapies if approved and adopted in clinical practice.

How Are Regulatory and Pricing Policies Impacting Investment?

Regulators increasingly scrutinize pricing, especially for high-cost inhalers. The Inflation Reduction Act and similar policies in Europe and other markets could pressure prices and reimbursement levels.

GSK's strategy involves navigating these policies while preserving profitability through portfolio diversification and innovation.

What Is the Outlook for Future Revenue?

With patent expiration and generic competition, revenue is projected to decline at a compound annual growth rate (CAGR) of approximately -5% from 2022 to 2025. However, pipeline contributions and growth in emerging markets could partially offset declines in mature markets.

Projected Revenue Trend Table:

Year	Projected Revenue	Change vs. Prior Year	Key Factors
2023	$3.7B	-3%	Generic market share expansion
2024	$3.5B	-5%	Continued patent cliff, pricing pressure
2025	$3.3B	-5.7%	Market saturation, biosimilar entry

What Are the Risks and Opportunities?

Risks	Opportunities
Patent expiration and generics	Development of next-generation inhalers and biologics
Regulatory pressure on pricing	Expanding into emerging markets
Competitive erosion	Increasing use of biologics for severe asthma

Final Assessment

ADVAIR DISKUS 100/50's market position is under pressure from patent expiry and generic competition. While current revenues are declining, GSK’s pipeline developments and market diversification strategies offer medium-term growth opportunities. Investors should gauge the timing of patent cliffs, generic entry, and pipeline approvals for strategic positioning.

Key Takeaways

• Revenue peaked pre-2018, with significant declines since due to patent expiry and generic competition.
• US market share reduced from 51% (2019) to 40% (2022).
• Future revenues will depend on pipeline success and market penetration of newer therapies.
• Regulatory and pricing policies pose downside risks; innovation and market expansion offer potential upside.
• GSK's strategic shift toward biologics and device innovation aims to offset declines from traditional inhalers.

FAQs

1. When do key patents for ADVAIR DISKUS expire?
Patent protections expired around 2017 in the U.S., with some formulations and device patents extending to 2022. Other markets may have different patent timelines.

2. How significant is the impact of generics on revenue?
Generic entries have led to over 20% declines in US sales annually since 2019, and further erosion is expected as more generics enter.

3. What are GSK’s pipeline priorities for respiratory diseases?
Focus on biologics for severe asthma, next-generation inhaler devices, and combination therapies targeting underserved patient populations.

4. How might regulatory changes affect ADVAIR DISKUS?
Pricing controls, reimbursement pressures, and biosimilar policies could further reduce profitability or slow sales growth.

5. What are the key growth markets for GSK’s respiratory portfolio?
Emerging markets such as China, India, and Latin America where inhaler penetration is increasing, represent strategic growth opportunities.

---

Sources:
[1] GSK Annual Reports (2019-2022)
[2] FDA Drug Approvals Database
[3] IQVIA Sales Data 2022
[4] GSK Pipeline Updates 2023